Literature DB >> 27259568

Impact of the introduction of a standardised ICD programming protocol: real-world data from a single centre.

Nicholas Sunderland1, Amit Kaura1, Anthony Li1, Ravi Kamdar1, Ed Petzer1, Para Dhillon1, Francis Murgatroyd1, Paul A Scott2.   

Abstract

PURPOSE: Randomised trials have shown that empiric ICD programming, using long detection times and high detection zones, reduces device therapy in ICD recipients. However, there is less data on its effectiveness in a "real-world" setting, especially secondary prevention patients. Our aim was to evaluate the introduction of a standardised programming protocol in a real-world setting of unselected ICD recipients.
METHODS: We analysed 270 consecutive ICD recipients implanted in a single centre-135 implanted prior to protocol implementation (physician-led group) and 135 after (standardised group). The protocol included long arrhythmia detection times (30/40 or equivalent) and high rate detection zones (primary prevention lower treatment zone 200 bpm). Programming in the physician-led group was at the discretion of the implanter. The primary endpoint was time-to-any therapy (ATP or shocks). Secondary endpoints were time-to-inappropriate therapy and time-to-appropriate therapy. The safety endpoints were syncopal episodes, hospital admissions and death.
RESULTS: At 12 months follow-up, 47 patients had received any ICD therapy (physician-led group, n = 31 vs. standardised group, n = 16). There was a 47 % risk reduction in any device therapy (p = 0.04) and an 86 % risk reduction in inappropriate therapy (p = 0.009) in the standardised compared to the physician-led group. There was a non-significant 30 % risk reduction in appropriate therapy (p = 0.32). Results were consistent across primary and secondary prevention patients. There were no significant differences in the rates of syncope, hospitalisation, and death.
CONCLUSIONS: In unselected patients in a real-world setting, introduction of a standardised programming protocol, using long detection times and high detection zones, significantly reduces the burden of ICD therapy without an increase in adverse outcomes.

Entities:  

Keywords:  High detection rate; Implantable cardioverter defibrillator; Inappropriate therapy; Long detection time; Shocks

Mesh:

Year:  2016        PMID: 27259568     DOI: 10.1007/s10840-016-0151-4

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  13 in total

1.  The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients.

Authors:  Avi Fischer; Kevin T Ousdigian; James W Johnson; Jeffrey M Gillberg; Bruce L Wilkoff
Journal:  Heart Rhythm       Date:  2011-08-09       Impact factor: 6.343

Review 2.  Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies.

Authors:  Brahmajee K Nallamothu; Rodney A Hayward; Eric R Bates
Journal:  Circulation       Date:  2008-09-16       Impact factor: 29.690

3.  Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial.

Authors:  Maurizio Gasparini; Alessandro Proclemer; Catherine Klersy; Axel Kloppe; Maurizio Lunati; José Bautista Martìnez Ferrer; Ahmad Hersi; Marcin Gulaj; Maurits C E F Wijfels; Elisabetta Santi; Laura Manotta; Angel Arenal
Journal:  JAMA       Date:  2013-05-08       Impact factor: 56.272

4.  Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks.

Authors:  Eleanor B Schron; Derek V Exner; Qing Yao; Louise S Jenkins; Jonathan S Steinberg; James R Cook; Steven P Kutalek; Peter L Friedman; Rosemary S Bubien; Richard L Page; Judy Powell
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

5.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

6.  Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review.

Authors:  S F Sears; J F Todaro; T S Lewis; W Sotile; J B Conti
Journal:  Clin Cardiol       Date:  1999-07       Impact factor: 2.882

7.  Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks.

Authors:  Marc T Silver; Laurence D Sterns; Jonathan P Piccini; Boyoung Joung; Chi-Keong Ching; Robert A Pickett; Rafael Rabinovich; Shufeng Liu; Brett J Peterson; Daniel R Lexcen
Journal:  Heart Rhythm       Date:  2014-11-07       Impact factor: 6.343

8.  Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.

Authors:  Bruce L Wilkoff; Brian D Williamson; Richard S Stern; Stephen L Moore; Fei Lu; Sung W Lee; Ulrika M Birgersdotter-Green; Mark S Wathen; Isabelle C Van Gelder; Brooke M Heubner; Mark L Brown; Keith K Holloman
Journal:  J Am Coll Cardiol       Date:  2008-08-12       Impact factor: 24.094

9.  Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.

Authors:  Jonathan Buber; David Luria; Osnat Gurevitz; David Bar-Lev; Michael Eldar; Michael Glikson
Journal:  Europace       Date:  2013-10-09       Impact factor: 5.214

10.  Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.

Authors:  Axel Kloppe; Alessandro Proclemer; Angel Arenal; Maurizio Lunati; José Bautista Martìnez Ferrer; Ahmad Hersi; Marcin Gulaj; Maurits C E F Wijffels; Elisabetta Santi; Laura Manotta; Lorenza Mangoni; Maurizio Gasparini
Journal:  Circulation       Date:  2014-05-16       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.